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Background: Computed tomography (CT) is the most common staging investigation in colorectal
cancer (CRC). Up to 25% of patients are found to have previously undetected hepatic lesions when
intraoperative ultrasound (IOUS) of the liver is used during CRC resection. We aimed to assess the ability
of IOUS to detect additional liver lesions/metastases at primary colorectal resection, and to evaluate
whether contrast-enhanced IOUS (CE-IOUS) improves the detection and characterization of hepatic
lesions.
Methods: We performed a single-centre, prospective pilot study. At CRC resection, patients underwent
IOUS of the liver. Contrast-enhanced IOUS of the liver was undertaken using i.v. sulphur hexafluoride
micro-bubbles (SonoVue®, 4.8 ml). Findings of CT, non-enhanced IOUS and CE-IOUS were compared.
Changes in staging or management were noted. Additional lesions were corroborated with iron oxide
magnetic resonance imaging (MRI).
Results: Among 21 patients, IOUS demonstrated additional lesions in seven (33%). Contrast altered the
diagnosis of non-enhanced IOUS in four (20%) and changed the management strategy in three (14%)
patients. Thus, IOUS in combination with the contrast agent altered the intraoperative or postoperative
management plan in four patients.
Conclusions: In the first study of its kind, early results suggest that the ability of IOUS to detect
additional metastases is improved by CE-IOUS, and that this may impact on surgical staging and
management.
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Introduction
Colorectal cancer (CRC) represents one of the commonest solid
tumours and accounted for almost a million cases worldwide in
2002, with mortality occurring in about half (529 000 deaths in
2002).1 Approximately 50–60% of patients with CRC develop liver
metastases during the course of their disease.2,3 Of these, 15–25%
present with synchronous liver metastases and an additional
20–25% develop metachronous metastases.4–6 Assuming an
annual incidence of a million cases, around 500 000 patients will
develop colorectal liver metastases (CLM) and subsequently
require some form of treatment.1
Hepatic resection offers by far the best opportunity for cure
from CLM. However, the majority of CLM patients have unresec-
table disease at presentation.7,8 Early detection improves the
chances of life-prolonging treatment in terms of both local and
systemic treatments. Therefore, it is desirable to detect CLM at an
early stage.
Multi-slice contrast-enhanced computed tomography (CT) is
the most commonly used preoperative staging investigation in
primary CRC for detecting metastases. The sensitivity of CT for
CLM is reported to be 73–85%.9,10 Previously undetected liver
metastases are still diagnosed at laparotomy in a significant pro-
portion of patients. However, metastases are often missed
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at laparotomy, either because they are too small or too deep to
palpate or because they are located in a liver segment inaccessible
to view. The routine use of intraoperative ultrasound (IOUS) of
the liver during primary CRC surgery is effective for detecting
additional lesions.11–13 However, around 15–20% of patients with
a negative IOUS develop liver metastases within 2 years of follow-
up.11,13 Although some of this later disease may be microscopic at
the time of IOUS, it is likely that some macroscopic lesions are
missed as a result of their small size or atypical characteristics,
because they mimic benign lesions or because they are iso-echoic
with the hepatic parenchyma and thus invisible. An imaging
modality with increased sensitivity and the capacity to disting-
uish benign from malignant with more clarity (and simplicity)
is needed.
Contrast agents have long been used to improve CT and
magnetic resonance imaging (MRI). Contrast-enhanced trans-
abdominal ultrasound is now available for routine use. The
i.v. micro-bubble (contrast) technology improves the accuracy of
detection of metastases and characterization of focal liver lesions
during trans-abdominal ultrasound, even to the extent of identi-
fying lesions missed by high-quality CT.14,15 This appears to extend
to IOUS during liver resection for CLM, when the clinical impact
can be immediate.16,17
The aim of our study was to assess the ability of IOUS to detect
additional liver lesions/metastases at primary CRC surgery, and to
evaluate whether contrast helps in the ultrasound detection and
characterization of focal liver lesions in this setting. We report the
first study using contrast-enhanced IOUS (CE-IOUS) of the liver
to detect and characterize additional hepatic lesions during
primary CRC resection.
Materials and methods
We report a prospective single-centre pilot study conducted
between April and December 2007 at a tertiary referral centre.
Regional ethics committee approval was obtained.
All patients underwent a multi-slice contrast-enhanced CT
of the chest, abdomen and pelvis as a preoperative staging inves-
tigation, at the same tertiary hospital. The CT scan of the chest,
abdomen and pelvis was performed with the Somatom® (Siemens
Plc, Frimley, UK), with pre-contrast CT followed by post-contrast
CT, using 1-mm cuts. The liver was analysed in all three phases
(non-contrast, arterial and porto-venous washout).
All the included patients had a diagnosis of adenocarcinoma of
the colon or rectum and were discussed by the CRC multidisci-
plinary team (MDT), which included two specialist gastrointesti-
nal radiologists. The position, size and CT characteristics of liver
lesions were then recorded in detail on a prospectively maintained
database. Based on the MDT decision, patients whose cancers were
amenable to curative open surgical resection were invited to par-
ticipate in this study. Full informed consent was obtained. Patients
who required emergency surgery (within 24 h of emergency hos-
pital admission) were excluded as they would not have enough time
to understand and consent to the contrast-enhanced scan.
At laparotomy, the liver was inspected and palpated for focal
hepatic lesions and the findings were noted. The laparotomy inci-
sion was a standard incision made by the colorectal surgeon to
remove the primary tumour; it was not extended to facilitate
IOUS/CE-IOUS. A non-enhanced B mode ultrasound examina-
tion (mechanical index 1.1) was performed at a frequency of
10 Mz by a surgeon trained to perform both non-enhanced and
contrast-enhanced ultrasound. We used the Bodedex-Korsolex
(B-K) Pro Focus 2202® scanner and 8815® intraoperative probe
(both B-K Medical ApS, Herlev, Denmark). A segment-by-
segment examination was performed in a standard manner. Data
recorded for each lesion included ultrasound characteristics, liver
segment(s) involved, a detailed description of the relationships of
the lesion to anatomical landmarks, an impression as to the
benign or malignant nature of the lesion and comments regarding
correlation with the CT data.
After the non-enhanced scan, the contrast, 25 mg of sulphur
hexafluoride micro-bubbles (SonoVue®; Bracco Imaging SpA,
Milan, Italy) diluted to 4.8 ml in saline, was prepared fresh by the
anaesthetist and injected i.v. through a peripheral wide-bore
cannula (16 G or 18 G). The cannula was then flushed with 10 ml
of normal saline. An on-screen timer was started and scanning
began immediately. Particular attention was paid to the classical
three phases of ultrasound contrast: the arterial phase (the
initial 30 s); the porto-venous phase (30 s to 2 min), and the
delayed parenchymal phase (2–5 min). The CE-IOUS was
performed using a standard mechanical index of
<0.18. The frequency of the probe was set at 4.3 MHz in
contrast-specific mode. The entire scanning period of 5 min was
recorded in digital video format. The non-enhanced images were
simultaneously visualized with low-frequency B mode on a dual-
screen mode. This facilitated anatomical localisation of newly
identified lesions.
Contrast-enhanced IOUS was always performed by starting
with a known metastatic or other benign lesion (on non-
enhanced IOUS) when present. The ipsi-lateral lobe was then
scanned on a segment-by-segment basis, followed by the con-
tralateral lobe. The characterization and location of lesions was
documented in detail. Changes in the surgical management plan
were noted. Where new lesions were identified, digital recordings
of real-time scans were also examined by a radiologist experienced
in contrast-enhanced trans-abdominal ultrasound.
We used MRI with liver-specific contrast (supermagnetic iron
oxide [SPIO]) particles as an interim reference standard for the
confirmation and characterization of additional lesions detected
with IOUS or CE-IOUS. The use of MRI with liver-specific
contrast also served two clinical purposes. Firstly, it provided a
roadmap of the metastases to aid in treatment planning. Secondly,
it provided a baseline from which to assess response to chemo-
therapy with subsequent MRI.
Patients without suspicious or new standard screening with
trans-abdominal ultrasound at 3 and 6 months with serum
carcino-embryonic antigen levels and a CT scan at 1 year.
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Neither the surgeon performing the IOUS nor the radiologist
were blinded to the findings of any of the investigation.
The findings of CT, non-enhanced IOUS and CE-IOUS were
compared. Changes in the surgical staging or management of
the disease were noted.
Statistical analysis
Statistical analysis was performed using spss Version 14.0. (SPSS,
Inc., Chicago, IL, USA). Statistics were applied as a percentile
difference between imaging modalities in the diagnosis of the
lesions, and the difference in the proportion of patients in whom
management strategies were altered. The difference is presented
with 95% confidence intervals.
Results
Twenty-one patients with CRC were enrolled in this prospective
pilot study over a 9-month period (April 2007 to December 2007).
The male : female ratio was 12 : 9. The median age of the patients
was 65 years (range 30–84 years).
Of the 21 patients, IOUS or CE-IOUS demonstrated additio-
nal or previously undetected liver lesions in seven patients. A
summary of the seven patients is reported in Table 1. The ultra-
sound (non-enhanced and contrast-enhanced) characteristics
of all identified lesions are detailed in Table 2. In these seven
patients, multi-slice CT had demonstrated four lesions, laparo-
tomy demonstrated six, non-enhanced IOUS demonstrated 17,
and CE-IOUS demonstrated 18 lesions. Thus a total of 14 new
lesions were diagnosed at IOUS + CE-IOUS. The entire liver scan-
ning procedure took an additional 10 min, although the time was
not recorded formally.
Non-enhanced IOUS demonstrated six new definitive meta-
stases in three patients. In another three patients, IOUS detected
lesions that were equivocal in their sonographic characteristics,
but suspicious for metastases considering the primary diagnosis.
Contrast confirmed the malignant nature of the lesions in the
first three patients and identified a further metastasis in one
of these patients. In the latter three, contrast defined equivocal
lesions as clearly benign in two patients and clearly malignant
in the third.
Contrast changed the diagnosis of non-enhanced IOUS in four
patients, by identifying the benign nature of equivocal lesions in
two patients and the malignant nature of an equivocal lesion
in one, and by detecting an additional metastasis in one patient.
SPIO-enhanced MRI corroborated these findings in these four
patients. The other three patients with new findings on IOUS/CE-
IOUS did not have MRI. One patient underwent an R2 resection
and had a complicated postoperative recovery. One patient had a
locally perforated tumour and four liver metastases on both IOUS
and CE-IOUS and underwent a palliative bypass. The last patient
had complete regression of the rectal cancer, on final histopathol-
ogy, as a result of preoperative chemoradiotherapy. The latter
patient had no evidence of metastases on a repeat CT scan. In each
of the four patients in whom contrast altered the detection or
characterization of lesions, the findings impacted on manage-
ment. The findings changed planned chemotherapy and further
consideration for liver resection in one patient, and changed
the type of liver resection planned in another. Benign contrast
characteristics prevented over-treatment in a third patient, and
the presence of several metastases aided the decision for bypass-
only for a difficult locally perforated primary lesion in the fourth
patient.
Three patients with rectal cancer underwent downstaging
chemoradiotherapy prior to resection. All of them had a repeat
staging CT scan after the downstaging and the cancers were
resected at 4–6 weeks after the repeat CT scan.
In the remaining 14 of the 21 patients no focal liver lesions were
seen. These patients did not undergo an MRI of the liver. There
was no evidence of hepatic metastases in these patients during
an outpatient clinic follow-up period that ranged between 9 and
16 months.
In summary, IOUS demonstrated additional lesions in seven
of 21 patients (33.3%, 95% confidence interval [CI] 14.6–57.0%).
Contrast changed the diagnosis compared with non-enhanced
IOUS in four patients (19.0%, 95% CI 5.4–41.9%). Intraoperative
US (with and without contrast) demonstrated previously unde-
tected metastases in three patients and changed management
in three patients (14.3%, 95% CI 3.0–36.3%). In one of these
patients, initially unilateral metastatic disease (on CT) was found
to be bilateral.
Discussion
In the first published study on contrast ultrasound of the liver
during primary CRC surgery, we have demonstrated that sulphur
hexafluoride CE-IOUS of the liver improves the detection of
hepatic metastases in patients with primary CRC. The demon-
strated improvement in hepatic staging in patients could (if
reproduced in other studies) have a significant impact on the
management of these patients.
None of the preoperative staging modalities used in CRC are as
accurate or sensitive as IOUS of the liver. This includes CT,13,18
positron emission tomography (PET)19 and probably MRI.20,21
In our study, CE-IOUS altered the diagnosis of non-enhanced
IOUS in 19% of patients. Although the frequency of detecting
additional lesions by CE-IOUS was similar to that of IOUS,
CE-IOUS seemed to more accurately characterize these lesions.
The better characterization of the lesions by the contrast material
is particularly advantageous in the setting of resection for primary
CRC, where equivocal lesions, which are statistically more sus-
picious for metastases, present a dilemma with important clinical
consequences.
The total scanning time of only 5 min is a potential limitation
in characterizing all lesions identified. However this can be over-
come by repeating the contrast injection for up to a total of 9.6 ml
of SonoVue®. Furthermore, once the sonographer is experienced,
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the vial of the contrast can be divided into two doses of 2.4 ml,
allowing up to four separate injections (using two vials). Sono-
Vue® probably does not provide enough time to perform
ultrasound-guided biopsy of lesions not visible with non-contrast
imaging. However, nearly all newly identified liver lesions in this
series were visible using non-enhanced IOUS and thus could
be biopsied without contrast, if appropriate. In the setting of CRC,
biopsy is not advisable for the majority of cases as it is known
to be associated with a worse longterm survival following liver
resection.22,23 Indeed, definitive imaging with contrast may reduce
the perceived need for biopsy.
The CE-IOUS findings were corroborated by CE-MRI in our
study. In the absence of histopathological proof of new IOUS/CE-
IOUS findings, it was felt appropriate to use the best non-invasive
modality for characterizing and detecting liver metastases.24–26
Contrast-enhanced MRI also provided a road map and baseline
for comparison for future management and follow-up. It would
be reasonable to argue that a routine preoperative CE-MRI could
be performed prior to CRC resection to improve staging.
However, in the setting of liver resection for CRC metastases,
it has been shown that IOUS provides the most sensitive and
predictive information.20,21 In a recent international multicentre
study, contrast-enhanced trans-abdominal ultrasound was reli-
able in detecting and characterizing focal liver lesions compared
with CT and MRI.27 This may be largely because cross-sectional
imaging continues to be limited in detecting and characterizing
sub-centimetre lesions.20,27 Contrast-enhanced IOUS would be
expected to produce better results than contrast-enhanced trans-
abdominal ultrasound because of the additional benefits of access
and of using higher-resolution non-enhanced IOUS. However,
there have also been clear and dramatic improvements in non-
enhanced IOUS alone over recent years and CE-IOUS cannot be
assumed to surpass these improvements.27 Therefore, as in liver
resection, the benefit of CE-IOUS over IOUS in the setting of
primary CRC requires testing.
This study was limited by the small and non-consecutive nature
of the cohort. The reasons for this were logistical and do not
indicate case selection. There was also a limited period of radio-
logical follow-up. Patients with normal CE-IOUS did not undergo
a follow-up MRI scan and the duration of further routine surveil-
lance imaging was short. However, to date, no patient with normal
CE-IOUS has developed recurrence in the liver. Existing data
strongly suggest that MRI in these cases would be unlikely to
reveal further disease.28 Although the impact of CE-IOUS may be
different in a larger consecutive series, it seems unlikely to be
negated.
Obstacles to routine hepatic IOUS or CE-IOUS in CRC resec-
tion include the need for additional operating time and specialist
equipment, both of which have financial and logistical implica-
tions. The logistics relate mainly to the availability of a trained
ultrasonographer in theatre. Despite several studies support-
ing liver IOUS during CRC resection, its routine use is
uncommon.11–13 One reason for this is a lack of ultrasound train-
ing for colorectal surgeons. However, it is likely that CE-IOUS
Table 2 Ultrasound characteristics of all identified lesions
Patient (age,
years/sex)
IOUS characteristics and impression CE-IOUS characteristics and impression
1 (73/M) 2 lesions – anechoic with no wall = cysts 2 lesions
Arterial phase: no rim enhancement
Portal and delayed phase: no contrast uptake
2 (77/F) a) Hypoechoic with irregular border = equivocal a) Arterial phase: hypo-intense with peripheral rim enhancement
Portal phase: rim enhancement fades
Delayed phase: dark defects (‘black holes’) on background of
bright parenchyma = metastasis (classical contrast appearance)
b) As patient 1 = cysts b) Cyst (as patient 1)
3 (82/F) a) Hyperechoic with irregular border = equivocal a/b) Continuous uptake of contrast, no ‘black holes’
Parenchyma bright in all 3 phases
b) Mildly hypoechoic, regular border = benign = benign
4 (61/M) 4 similar lesions Classical contrast appearance of metastases (‘black hole’)
(1 lesion not visible in delayed phase)Hypoechoic rim, hyperechoic centre (classical
appearance of metastases)
5 (30/F) 2 lesions 3 lesions
a) Classical appearance = metastasis a) Classical metastasis (‘black hole’)
b) Centripetal filling in delayed and portal phase, brighter than
contrast bright parenchyma = haemangiomab) Hyperechoic with posterior enhancement
c) Classical metastasis
6 (77/F) Classical appearance = metastases Classical metastases
7 (65/M) Hyperechoic with irregular border = equivocal As patient 3 = benign
IOUS, intraoperative ultrasound; CE-IOUS, contrast-enhanced intraoperative ultrasound; M, male; F, female
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would facilitate the training process, because contrast produces
more definitive images, which serve to confirm or negate the
impression gained from non-contrast images, and thus provide a
means of self training.14 This may be especially true with newer
agents, which give a slower washout of contrast, potentially
leading to improved training opportunities and metastasis detec-
tion rates.29 The financial implications of routine CE-IOUS would
be relatively minimal compared with the benefits likely to result
from the earlier detection of liver metastases and the consequent
improvements in survival.
Liver resection at the time of primary CRC resection has been
shown to be safe and overall is associated with fewer complica-
tions.30 The confident use of IOUS and CE-IOUS by colorectal
surgeons may provide opportunities for this treatment option in
a greater number of cases. In our own experience, even when a
combined resection is not to be considered, an accurate descrip-
tion of intraoperative findings by the colorectal surgeon is invalu-
able when considering cases for future liver resection.
Conclusions
The preliminary results of this study suggest that in the setting of
current standard preoperative imaging, high-resolution intraop-
erative ultrasound of the liver during colorectal primary resection
demonstrates additional hepatic lesions. In this setting, character-
ization of hepatic lesions is improved by the addition of sulphur
hexafluoride micro-bubble contrast agent. This may lead to an
impact on the surgical staging and treatment of lesions.
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